

Three cases of intravenous sodium benzoate and sodium phenylacetate toxicity occurring in the treatment of acute hyperammonaemia

V. PRAPHANPHOJ¹, S. A. BOYADJIEV¹, L. J. WABER², S. W. BRUSILOW¹ and M. T. GERAGHTY¹

¹ *Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland;* ² *University of Texas Southwestern Medical School, Dallas, Texas, USA*

* *Correspondence: Department of Pediatrics, Blalock 1008, Johns Hopkins University School of Medicine, 600 N. Wolfe St., Baltimore, MD 21287-4922, USA*

MS received 24.12.98 Accepted 13.08.99

Summary: Intravenous sodium benzoate and sodium phenylacetate have been used successfully in the treatment of acute hyperammonaemia in patients with urea cycle disorders. They provide alternative pathways for waste nitrogen disposal and help maintain nitrogen homeostasis. However, we report three patients with hyperammonaemia who received inappropriate doses of intravenous sodium benzoate and sodium phenylacetate that resulted in severe complications. Ambiguous medical prescriptions and inadequate cross-checking of drug dosage by physicians, nurses and pharmacists were the main causes of these incidents. All the patients presented with alteration in mental status, Kussmaul respiration and a partially compensated metabolic acidosis with an increased anion gap. Two patients developed cerebral oedema and hypotension and died. The third survived after haemodialysis. Plasma levels of benzoate and phenylacetate were excessively high. The possible mechanisms of toxicity, management and safety measures are discussed.

Intravenous sodium benzoate and sodium phenylacetate have been used successfully in the treatment of episodic hyperammonaemia in patients with urea cycle disorders (Brusilow et al 1984). These drugs provide alternative pathways to ureagenesis for waste nitrogen disposal and help maintain nitrogen homeostasis in these patients. Sodium benzoate is conjugated with glycine to form hippurate, while sodium phenylacetate is conjugated with glutamine to form phenylacetylglutamine. Both of these metabolites are rapidly excreted in urine via glomerular filtration and tubular secretion. The recommended dose of intravenous sodium benzoate and sodium phenylacetate is 250 mg/kg each infused over 90 min, followed thereafter by 250 mg/kg each infused over 24 h. Theoretically, administration of 250 mg/kg per day of each drug

will lead to an excretion of 24 mg/kg per day of hippurate nitrogen or 44 mg/kg per day of phenylacetylglutamine nitrogen (Brusilow and Maestri 1996).

These investigational drugs have been used in the treatment of patients with urea cycle defects for almost 20 years and the effectiveness and safety of this therapy is widely accepted. The success of the drugs in decreasing plasma ammonium levels in these disorders has led to their wider application to the treatment of hyperammonaemia from other causes (Mendenhall et al 1986; Tse et al 1991). Known side-effects of the drugs include nausea and vomiting during the infusion and hypokalaemia secondary to urinary loss enhanced by the excretion of the non-absorbable anions (hippurate and phenylacetylglutamine) (Batshaw et al 1982). Hyperchloraemic acidosis may occur as a consequence of arginine-HCl administration. No serious side-effects have been reported when the drugs are used in the recommended doses. However, we report here three cases of hyperammonaemic patients who received excessive doses of intravenous sodium benzoate and sodium phenylacetate, resulting in devastating complications.

MATERIALS AND METHODS

We reviewed the hospital charts of three patients who received accidental overdose with intravenous sodium benzoate and sodium phenylacetate. All three patients had known urea cycle defects and were being treated for intercurrent acute hyperammonaemia at the time the overdose occurred. Two cases occurred at one hospital and the third at a separate hospital. The clinical courses, relevant laboratory results including blood gases, electrolytes and ammonium levels, details of drug dosage, and drug and drug metabolite levels were summarized.

Plasma ammonium was measured by a cation-ion exchange method (Brusilow 1991). In our laboratory, the normal plasma ammonium levels are less than 30 $\mu\text{mol/L}$. Where possible, blood for determination of drug levels and drug metabolites was obtained. Plasma benzoate, hippurate, phenylacetate and phenylacetylglutamine were determined by reversed-phase high-pressure liquid chromatography (Batshaw et al 1982).

PATIENT 1

J.H., a 3-year-old girl with known ornithine transcarbamylase deficiency, presented with a 2-day history of upper respiratory tract infection. Subsequently, she became irritable with decreased mental alertness. At the time of admission her diet was protein restricted (1 g/kg per day natural protein) and she was taking 2.5 g/day of sodium benzoate and sodium phenylacetate and 3.6 g/day of citrulline. On admission her weight was 11.6 kg. Initial laboratory results showed a plasma ammonium of 82 $\mu\text{mol/L}$. Serum electrolytes were sodium 141 mEq/L, potassium 4.0 mEq/L, chloride 103 mEq/L, bicarbonate 21 mEq/L and glucose 67 mg/dL. At that time her quantitative amino acids showed glutamine 1056 $\mu\text{mol/L}$ (337–673), glycine 296 $\mu\text{mol/L}$ (87–323), alanine 948 $\mu\text{mol/L}$ (136–440), citrulline 0 $\mu\text{mol/L}$ (10–34), ornithine 108 $\mu\text{mol/L}$ (22–94), arginine 20 $\mu\text{mol/L}$ (15–115); normal laboratory values are shown in parentheses. Because of altered mental status, a priming intra-

J. Inherit. Metab. Dis. 23 (2000)

venous dose of 250 mg/kg of sodium benzoate and sodium phenylacetate with 2 ml/kg of 10% arginine-HCl was ordered to be given over 90 min, followed by the same dose over 24 h. Her plasma ammonium level decreased to 44 $\mu\text{mol/L}$ and 54 $\mu\text{mol/L}$ at 4 and 7 h, respectively, after starting treatment. Plasma amino acids 4 h after starting treatment showed glutamine 745 $\mu\text{mol/L}$ (337–673), glycine 85 $\mu\text{mol/L}$ (87–323), alanine 998 $\mu\text{mol/L}$ (136–440), citrulline trace (10–34), ornithine 237 $\mu\text{mol/L}$ (22–94), arginine 776 $\mu\text{mol/L}$ (15–115). However, during this time she became more irritable and somnolent, and developed tachypnoea with Kussmaul respiration. A repeat venous blood gas 7 h after starting the intravenous drugs showed a pH of 7.21 and $p\text{CO}_2$ of 5 torr. Serum electrolytes at that time were sodium 146 mEq/L, potassium 3.7 mEq/L, chloride 104 mEq/L and bicarbonate 4 mEq/L, with a calculated anion gap of 42. She was transferred to the intensive care unit, where her condition worsened. Her plasma ammonium levels increased to 158 $\mu\text{mol/L}$ and 232 $\mu\text{mol/L}$ at 22 and 26 h, respectively, despite continuous infusion of both medications. Serum electrolytes at 26 h were sodium 152 mEq/L, potassium 2.9 mEq/L, chloride 107 mEq/L and bicarbonate 16 mEq/L, with a calculated anion gap of 32. Haemodialysis was required to correct her acid–base balance and hyperammonaemia. Plasma ammonium decreased below 100 $\mu\text{mol/L}$ and her anion gap normalized within 24 h. Plasma ammonium levels were normal by 48 h.

Plasma taken 4 h after the priming dose was ordered, and at the time of the increased anion gap, revealed levels of benzoate and phenylacetate far above those reported for the recommended doses (Table 1). Retrospective review of the medical record revealed that the patient had received three priming doses intravenously followed by an incorrect maintenance infusion dose. In total the patient received 915 mg/kg of sodium benzoate and sodium phenylacetate over 12 h. The written orders were ambiguous and the abnormal dose went unrecognized by pharmacists, nurses and physicians. She recovered from the event and was discharged home after 17 days of admission. She is now 19 years of age with an overall DQ of 35. She continues to have occasional episodes of hyperammonaemia despite treatment with a protein-restricted diet (0.75 g/kg per day) supplemented with sodium phenylbutyrate (500 mg/kg per day) and citrulline.

PATIENT 2

S.P., a boy aged 6 years and 8 months with known late-onset ornithine transcarbamylase deficiency, presented with vomiting and a possible viral illness. His weight on admission was 21 kg. Prior to admission the patient was on a protein-restricted diet with citrulline supplementation. However, the family was noncompliant. His initial plasma ammonium was 326 $\mu\text{mol/L}$. Serum electrolytes were sodium 141 mEq/L, potassium 4.7 mEq/L, chloride 103 mEq/L, bicarbonate 23 mEq/L, with an anion gap of 20. Plasma amino acids were not obtained. He was admitted and treated with a priming dose of 250 mg/kg of sodium benzoate and sodium phenylacetate with 2 ml/kg of 10% arginine-HCl infused over 2 h. This resulted in a decline of the plasma ammonium to 78 $\mu\text{mol/L}$ one hour after com-

J. Inherit. Metab. Dis. 23 (2000)

Table 1 Drug levels and metabolites obtained in patients 1 and 3

<i>Time (h)</i>	<i>BA (mmol/L)</i>	<i>PA (mmol/L)</i>	<i>HA (mmol/L)</i>	<i>PAG (mmol/L)</i>
Patient 1				
0	0.002	ND	0.007	ND
4	10.60	10.0	0.292	ND
12	1.80	2.71	0.294	0.097
Patient 3				
6	5.07	8.19	0.399	0.341
9	5.58	9.07	0.395	0.341
13	3.37	7.67	0.362	0.292
15	2.53	8.16	0.412	0.319
19	0.321	7.59	0.566	0.475
28	0.034	1.79	0.189	0.677
Normal values				
0	0	0	0	0
3	2.6	3.4	0.25	0
12	1.5	4.5	0.35	0
17	0.2	3.5	0.25	0.40
20	0	3.0	0.15	0.50
27	0	2.2	0.15	0.50
32	0.4	1.5	0.15	0.45

For comparison, values are shown from a single patient who received 250 mg/kg over 90 min followed by 250 mg/kg over 24 h

BA, benzoate; PA, phenylacetate; HA, hippurate; PAG, phenylacetylglutamine; ND, not determined.

pletion of the priming infusion. Since he was unable to take his oral medication, a 24 h infusion of the same dose of each medication was ordered. At 16 h of this infusion, he was found to be obtunded and unresponsive to painful stimuli and had Kussmaul respiration. His plasma ammonium was 113 $\mu\text{mol/L}$. A venous gas showed a pH of 7.38, $p\text{CO}_2$ of 9 torr and a calculated bicarbonate of 5 mEq/L. Serum electrolytes were sodium 151 mEq/L, potassium 2.7 mEq/L, chloride 97 mEq/L and bicarbonate < 5 mEq/L. The calculated anion gap was 52 mEq/L. An overdose of intravenous sodium benzoate and sodium phenylacetate was suspected at that time and the infusion was stopped at approximately 18 h. He was then treated with intravenous fluids and sodium bicarbonate. However, his plasma ammonium increased to 915 $\mu\text{mol/L}$. At that time his venous blood gas showed a pH of 7.35 and a $p\text{CO}_2$ of 12 torr. His serum electrolytes were sodium 152 mEq/L, potassium 3.5 mEq/L, chloride 101 mEq/L and bicarbonate 6 mEq/L. The calculated anion gap was 49 mEq/L. Haemodialysis was started and his acid-base balance and ammonium levels were normalized after two rounds of dialysis. Despite this, his neurological status worsened, a CT scan of his brain showed cerebral oedema and he had fixed and dilated pupils. He was pronounced dead on the third day of admission.

A review of the medical record revealed that the patient had received the entire 24 h continuous infusion dose repeating every 3 h resulting in a total dose of 1750 mg/kg of sodium benzoate and sodium phenylacetate over an 18 h period.

J. Inherit. Metab. Dis. 23 (2000)

Again medical orders were ambiguous and the excessive doses were not recognized by pharmacists, nurses or physicians. He had received seven times the desired dose within 18 h until the time his clinical condition deteriorated and the infusion was stopped. Drug levels were not available.

PATIENTS 3

D.D., a boy aged 2 years and 9 months with known neonatal-onset ornithine transcarbamylase deficiency, was admitted following 1 week of upper respiratory tract infection and 2 days of emesis and irritability. At the time of his illness his diet consisted of 1.28 g/kg per day of protein, of which 0.5 g/kg per day was given as essential amino acids (UCD2, Milupa). Additionally, he was taking 600 mg/kg per day of phenylbutyrate and 3 g/day of citrulline. On admission he was alert and active with stable vital signs. His weight was 13 kg. The initial plasma ammonium was 84 $\mu\text{mol/L}$. A venous blood gas showed a pH of 7.38, and $p\text{CO}_2$ of 35 torr. Serum electrolytes were sodium 142 mEq/L, potassium 4.4 mEq/L, chloride 110 mEq/L, bicarbonate 22 mEq/L and a calculated anion gap of 14. Quantitative plasma amino acids showed glutamine 1446 $\mu\text{mol/L}$ (337–673), glycine 390 $\mu\text{mol/L}$ (87–323), alanine 2198 $\mu\text{mol/L}$ (136–440), citrulline 0 (10–34), ornithine 50 $\mu\text{mol/L}$ (22–94), arginine 39 $\mu\text{mol/L}$ (15–115). Because of continued vomiting, a priming dose of 250 mg/kg sodium benzoate, 250 mg/kg sodium phenylacetate and 2 ml/kg 10% arginine-HCl was started. Maintenance with the same doses and medications was ordered to run over 24 h after the priming dose was completed. Six hours after starting the priming dose, the patient's plasma ammonium had decreased to 32 $\mu\text{mol/L}$. Plasma amino acids at that time showed glutamine 806 $\mu\text{mol/L}$ (337–673), glycine 60 $\mu\text{mol/L}$ (87–323), alanine 995 $\mu\text{mol/L}$ (136–440), citrulline 0 (10–34), ornithine 148 $\mu\text{mol/L}$ (22–94), arginine 377 $\mu\text{mol/L}$ (15–115). However, after 9 h of treatment he was noted to be lethargic and irritable and had Kussmaul respiration. Serum electrolytes at that time were sodium 137 mEq/L, potassium 4.2 mEq/L, chloride 97 mEq/L, and bicarbonate 5 mEq/L. The calculated anion gap was 39 mEq/L. At that time it was discovered that he was receiving an incorrect maintenance dose. The medications were immediately stopped but despite vigorous fluid and electrolyte resuscitation he developed cerebral oedema and respiratory depression requiring ventilatory support. The patient developed disseminated intravascular coagulation, became hypotensive and died within 36 h of admission.

Drug levels (Table 1) revealed toxic levels of benzoate, phenylacetate and their metabolites. Review of the medical record revealed that the patient received a total of 750 mg/kg of the drugs over 10 h. The orders for the drugs were wrongly transcribed and the mistake was not recognized by pharmacists, nurses or physicians.

DISCUSSION

The recommended dose of intravenous sodium benzoate and sodium phenylacetate is 250 mg/kg each infused over 90 min, followed by 250 mg/kg each infused over 24 h

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.